AIM: Mucins comprise a family of high-molecular-weight glycoproteins. MUC4, a large transmembrane mucin, has recently emerged as a novel marker for diagnosis, prognosis and therapy in several malignancies. However, its role in skin pathologies remains unknown. The aim of this study was to analyse the expression of MUC4 in cutaneous pathologies by immunohistochemistry for potential diagnostic, prognostic and therapeutic applications. METHODS: A total of 330 tissue spots representing the normal skin, and benign and malignant cutaneous diseases, were analysed after staining with the monoclonal antibody to human MUC4 (clone 8G7). RESULTS: While the normal epidermis showed a negative to weak-positive expression of MUC4, its expression was significantly upregulated in squamous cell carcinomas (SCCs) where the intensity of staining correlated negatively with tumour grade and positively with age. A moderately strong MUC4 expression was also noted in 2/20 cancer adjacent normal skin and 2/21 chronically inflamed skin tissues, while 10/19 cases of vulval condyloma acuminate, 3/12 of vulval hyperplasia and 2 cases of verruca vulgaris also showed strong MUC4 positivity. Malignant melanoma, basal cell carcinoma and cutaneous cysts were negative. CONCLUSION: The results indicate that MUC4 expression is aberrantly upregulated in cutaneous SCCs, vulval condylomas and verruca vulgaris. Further, it appears that MUC4 expression in the skin may be modulated by chronic inflammation and the presence of an adjacent cutaneous malignancy in certain cases. These observations suggest a novel role for MUC4 mucin in the pathogenesis of cutaneous SCC and a possible application as a diagnostic and/or prognostic marker in cutaneous pathologies.
AIM: Mucins comprise a family of high-molecular-weight glycoproteins. MUC4, a large transmembrane mucin, has recently emerged as a novel marker for diagnosis, prognosis and therapy in several malignancies. However, its role in skin pathologies remains unknown. The aim of this study was to analyse the expression of MUC4 in cutaneous pathologies by immunohistochemistry for potential diagnostic, prognostic and therapeutic applications. METHODS: A total of 330 tissue spots representing the normal skin, and benign and malignant cutaneous diseases, were analysed after staining with the monoclonal antibody to humanMUC4 (clone 8G7). RESULTS: While the normal epidermis showed a negative to weak-positive expression of MUC4, its expression was significantly upregulated in squamous cell carcinomas (SCCs) where the intensity of staining correlated negatively with tumour grade and positively with age. A moderately strong MUC4 expression was also noted in 2/20 cancer adjacent normal skin and 2/21 chronically inflamed skin tissues, while 10/19 cases of vulval condyloma acuminate, 3/12 of vulval hyperplasia and 2 cases of verruca vulgaris also showed strong MUC4 positivity. Malignant melanoma, basal cell carcinoma and cutaneous cysts were negative. CONCLUSION: The results indicate that MUC4 expression is aberrantly upregulated in cutaneous SCCs, vulval condylomas and verruca vulgaris. Further, it appears that MUC4 expression in the skin may be modulated by chronic inflammation and the presence of an adjacent cutaneous malignancy in certain cases. These observations suggest a novel role for MUC4mucin in the pathogenesis of cutaneous SCC and a possible application as a diagnostic and/or prognostic marker in cutaneous pathologies.
Authors: Adam I Riker; Steven A Enkemann; Oystein Fodstad; Suhu Liu; Suping Ren; Christopher Morris; Yaguang Xi; Paul Howell; Brandon Metge; Rajeev S Samant; Lalita A Shevde; Wenbin Li; Steven Eschrich; Adil Daud; Jingfang Ju; Jaime Matta Journal: BMC Med Genomics Date: 2008-04-28 Impact factor: 3.063
Authors: Subhash C Chauhan; Ajay P Singh; Fernanda Ruiz; Sonny L Johansson; Maneesh Jain; Lynette M Smith; Nicolas Moniaux; Surinder K Batra Journal: Mod Pathol Date: 2006-07-28 Impact factor: 7.842
Authors: Pallavi Chaturvedi; Ajay P Singh; Nicolas Moniaux; Shantibhushan Senapati; Subhankar Chakraborty; Jane L Meza; Surinder K Batra Journal: Mol Cancer Res Date: 2007-04-03 Impact factor: 5.852
Authors: Elizabeth G Munro; Maneesh Jain; Esther Oliva; Neel Kamal; Subodh M Lele; Maureen P Lynch; Lankai Guo; Kai Fu; Poonam Sharma; Steve Remmenga; Whitfield B Growdon; John S Davis; Bo R Rueda; Surinder K Batra Journal: Int J Gynecol Pathol Date: 2009-03 Impact factor: 2.762
Authors: S Senapati; P Chaturvedi; P Sharma; G Venkatraman; J L Meza; W El-Rifai; H K Roy; S K Batra Journal: Br J Cancer Date: 2008-09-16 Impact factor: 7.640
Authors: N Moniaux; S Chakraborty; M Yalniz; J Gonzalez; V K Shostrom; J Standop; S M Lele; M Ouellette; P M Pour; A R Sasson; R E Brand; M A Hollingsworth; M Jain; S K Batra Journal: Br J Cancer Date: 2008-04-08 Impact factor: 7.640
Authors: S Kumar; S Das; S Rachagani; S Kaur; S Joshi; S L Johansson; M P Ponnusamy; M Jain; S K Batra Journal: Oncogene Date: 2014-12-22 Impact factor: 9.867
Authors: Dhanya Haridas; Subhankar Chakraborty; Moorthy P Ponnusamy; Imayavaramban Lakshmanan; Satyanarayana Rachagani; Eric Cruz; Sushil Kumar; Srustidhar Das; Subodh M Lele; Judy M Anderson; Uwe A Wittel; Michael A Hollingsworth; Surinder K Batra Journal: PLoS One Date: 2011-10-31 Impact factor: 3.240